64 related articles for article (PubMed ID: 20042973)
1. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
Sridhar SS; Hotte SJ; Chin JL; Hudes GR; Gregg R; Trachtenberg J; Wang L; Tran-Thanh D; Pham NA; Tsao MS; Hedley D; Dancey JE; Moore MJ
Am J Clin Oncol; 2010 Dec; 33(6):609-13. PubMed ID: 20042973
[TBL] [Abstract][Full Text] [Related]
2. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.
Iqbal S; Goldman B; Fenoglio-Preiser CM; Lenz HJ; Zhang W; Danenberg KD; Shibata SI; Blanke CD
Ann Oncol; 2011 Dec; 22(12):2610-2615. PubMed ID: 21415234
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Leslie KK; Sill MW; Lankes HA; Fischer EG; Godwin AK; Gray H; Schilder RJ; Walker JL; Tewari K; Hanjani P; Abulafia O; Rose PG
Gynecol Oncol; 2012 Nov; 127(2):345-50. PubMed ID: 22885469
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
Whang YE; Armstrong AJ; Rathmell WK; Godley PA; Kim WY; Pruthi RS; Wallen EM; Crane JM; Moore DT; Grigson G; Morris K; Watkins CP; George DJ
Urol Oncol; 2013 Jan; 31(1):82-6. PubMed ID: 21396844
[TBL] [Abstract][Full Text] [Related]
5. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.
Crown J; Kennedy MJ; Tresca P; Marty M; Espie M; Burris HA; DeSilvio M; Lau MR; Kothari D; Koch KM; Diéras V
Ann Oncol; 2013 Aug; 24(8):2005-11. PubMed ID: 23878115
[TBL] [Abstract][Full Text] [Related]
6. Communication between cells: exosomes as a delivery system in prostate cancer.
Giovannelli P; Di Donato M; Galasso G; Monaco A; Licitra F; Perillo B; Migliaccio A; Castoria G
Cell Commun Signal; 2021 Nov; 19(1):110. PubMed ID: 34772427
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate.
Wu WF; Wang L; Spetsieris N; Boukovala M; Efstathiou E; Brössner C; Warner M; Gustafsson JA
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33771918
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived xenografts and organoids model therapy response in prostate cancer.
Karkampouna S; La Manna F; Benjak A; Kiener M; De Menna M; Zoni E; Grosjean J; Klima I; Garofoli A; Bolis M; Vallerga A; Theurillat JP; De Filippo MR; Genitsch V; Keller D; Booij TH; Stirnimann CU; Eng K; Sboner A; Ng CKY; Piscuoglio S; Gray PC; Spahn M; Rubin MA; Thalmann GN; Kruithof-de Julio M
Nat Commun; 2021 Feb; 12(1):1117. PubMed ID: 33602919
[TBL] [Abstract][Full Text] [Related]
9. Self-Assembly of pH-Labile Polymer Nanoparticles for Paclitaxel Prodrug Delivery: Formulation, Characterization, and Evaluation.
Levit SL; Gade NR; Roper TD; Yang H; Tang C
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291475
[TBL] [Abstract][Full Text] [Related]
10. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.
Zhang Z; Karthaus WR; Lee YS; Gao VR; Wu C; Russo JW; Liu M; Mota JM; Abida W; Linton E; Lee E; Barnes SD; Chen HA; Mao N; Wongvipat J; Choi D; Chen X; Zhao H; Manova-Todorova K; de Stanchina E; Taplin ME; Balk SP; Rathkopf DE; Gopalan A; Carver BS; Mu P; Jiang X; Watson PA; Sawyers CL
Cancer Cell; 2020 Aug; 38(2):279-296.e9. PubMed ID: 32679108
[TBL] [Abstract][Full Text] [Related]
11. Sequential Ras/MAPK and PI3K/AKT/mTOR pathways recruitment drives basal extrusion in the prostate-like gland of Drosophila.
Rambur A; Lours-Calet C; Beaudoin C; Buñay J; Vialat M; Mirouse V; Trousson A; Renaud Y; Lobaccaro JA; Baron S; Morel L; de Joussineau C
Nat Commun; 2020 May; 11(1):2300. PubMed ID: 32385236
[TBL] [Abstract][Full Text] [Related]
12. Rapid Self-Assembly of Polymer Nanoparticles for Synergistic Codelivery of Paclitaxel and Lapatinib via Flash NanoPrecipitation.
Levit SL; Yang H; Tang C
Nanomaterials (Basel); 2020 Mar; 10(3):. PubMed ID: 32244904
[TBL] [Abstract][Full Text] [Related]
13. Cellular rewiring in lethal prostate cancer: the architect of drug resistance.
Carceles-Cordon M; Kelly WK; Gomella L; Knudsen KE; Rodriguez-Bravo V; Domingo-Domenech J
Nat Rev Urol; 2020 May; 17(5):292-307. PubMed ID: 32203305
[TBL] [Abstract][Full Text] [Related]
14. Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.
Jathal MK; Steele TM; Siddiqui S; Mooso BA; D'Abronzo LS; Drake CM; Whang YE; Ghosh PM
Br J Cancer; 2019 Jul; 121(3):237-248. PubMed ID: 31209328
[TBL] [Abstract][Full Text] [Related]
15. Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis.
Foj L; Filella X
Pathol Oncol Res; 2019 Oct; 25(4):1445-1456. PubMed ID: 30367364
[TBL] [Abstract][Full Text] [Related]
16. The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.
Mandel A; Larsson P; Sarwar M; Semenas J; Syed Khaja AS; Persson JL
Mol Med; 2018 Jun; 24(1):34. PubMed ID: 30134822
[TBL] [Abstract][Full Text] [Related]
17. Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.
Patel R; Fleming J; Mui E; Loveridge C; Repiscak P; Blomme A; Harle V; Salji M; Ahmad I; Teo K; Hamdy FC; Hedley A; van den Broek N; Mackay G; Edwards J; Sansom OJ; Leung HY
EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29540470
[TBL] [Abstract][Full Text] [Related]
18. Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.
Stein S; Zhao R; Haeno H; Vivanco I; Michor F
PLoS Comput Biol; 2018 Jan; 14(1):e1005924. PubMed ID: 29293494
[TBL] [Abstract][Full Text] [Related]
19. A Standardized
Tsai CH; Tzeng SF; Hsieh SC; Tsai CJ; Yang YC; Tsai MH; Hsiao PW
Front Pharmacol; 2017; 8():721. PubMed ID: 29066975
[TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes.
Kharmate G; Hosseini-Beheshti E; Caradec J; Chin MY; Tomlinson Guns ES
PLoS One; 2016; 11(5):e0154967. PubMed ID: 27152724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
